首页 > 最新文献

Journal of Urology最新文献

英文 中文
Gene Therapy With URO-902 (pVAX/hSlo) for the Treatment of Female Patients With Overactive Bladder and Urge Urinary Incontinence: Safety and Efficacy From a Randomized Phase 2a Trial. 基因治疗eu -902 (pVAX/hSlo)治疗女性膀胱过动症和急迫性尿失禁:来自随机2a期试验的安全性和有效性
IF 5.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-04-01 Epub Date: 2024-12-18 DOI: 10.1097/JU.0000000000004373
Ekene A Enemchukwu, Susan Kalota, Kaiser Robertson, Sijian Ge, Jingmei Lu, Hanh Badger, Salim Mujais, Kenneth M Peters

Purpose: We assessed efficacy and safety of URO-902, an investigational gene therapy expressing the α subunit of the large-conductance Ca2+-activated K+ channel, in a phase 2a placebo-controlled trial in women with overactive bladder (OAB).

Materials and methods: Women, age 40 to 79 years, with OAB and urge urinary incontinence who were refractory to OAB medications were randomized to single-dose URO-902 24 and 48 mg or placebo administered by intradetrusor injection via cystoscopy under local anesthesia. Efficacy end points included change from baseline to week 12 in mean daily micturitions, urgency episodes, urge urinary incontinence episodes, and patient-reported outcomes. Safety assessments included adverse events and postvoid residual urine volume.

Results: Of 80 patients randomized (URO-902 24 mg, n = 26; URO-902 48 mg, n = 27; placebo, n = 27), 74 received treatment, and 67 reached week 24. At week 12, URO-902 24 and 48 mg were associated with significant improvement vs placebo in daily micturitions (least-squares mean change from baseline, -2.3 and -2.4 vs -0.8, respectively; least-squares mean difference [95% CI], ‒1.5 [‒2.7 to ‒0.3] and ‒1.6 [‒2.8 to ‒0.4], nominal P = .017 and P = .009, respectively). URO-902 48 mg was associated with significant improvements vs placebo in urgency episodes (‒3.4 vs ‒1.1; ‒2.2 [‒4.0 to ‒0.4]; nominal P = .016) and percentage of Patient Global Impression of Change responders (58% vs 31%; nominal P = .026). Among patients receiving URO-902 24 mg, URO-902 48 mg, and placebo, 46%, 54%, and 54%, respectively, experienced ≥ 1 treatment-emergent adverse events, most commonly UTI (0%, 15%, 4%) and hematuria (6%, 8%, 8%).

Conclusions: In this phase 2a trial, treatment with URO-902 was associated with improvements vs placebo in efficacy and patient-reported outcomes and was safe and well tolerated.

目的:在一项2a期安慰剂对照试验中,评估uroo -902的有效性和安全性。uroo -902是一种表达大电导Ca2+激活K+通道α亚基的基因疗法。材料和方法:40-79岁的OAB和急发性尿失禁(UUI)女性,对OAB药物难治,随机分为单剂量uro - 90224mg和48mg或安慰剂组,局部麻醉下经膀胱镜下肌内注射。疗效终点包括从基线到第12周的平均每日排尿、急症发作、UUI发作和患者报告的结果的变化。安全性评估包括不良事件(ae)和尿后残留量。结果:80例随机患者(uroo -902 24 mg, n=26;eu -902 48 mg, n=27;安慰剂组(n=27), 74人接受治疗,67人活到第24周。在第12周,与安慰剂相比,24和48 mg的URO-902在每日排尿方面有显著改善(基线的最小二乘平均变化,-2.3和-2.4 vs -0.8;最小二乘平均差[95%置信区间],-1.5[-2.7至-0.3]和-1.6[-2.8至-0.4],名义P分别=0.017和P=0.009)。与安慰剂相比,48 mg的eu -902在急症发作中有显著改善(-3.4 vs -1.1;-2.2[-4.0至-0.4];名义P=0.016)和患者对变化的总体印象应答者的百分比(58% vs 31%;名义P = 0.026)。在接受uro - 90224mg、48mg和安慰剂治疗的患者中,分别有46%、54%和54%的患者发生≥1次治疗性不良反应,最常见的是尿路感染(0%、15%、4%)和血尿(6%、8%、8%)。结论:在这项2a期试验中,与安慰剂相比,使用eu -902治疗在疗效和患者报告的结果方面有所改善,并且安全性和耐受性良好。
{"title":"Gene Therapy With URO-902 (pVAX/<i>hSlo</i>) for the Treatment of Female Patients With Overactive Bladder and Urge Urinary Incontinence: Safety and Efficacy From a Randomized Phase 2a Trial.","authors":"Ekene A Enemchukwu, Susan Kalota, Kaiser Robertson, Sijian Ge, Jingmei Lu, Hanh Badger, Salim Mujais, Kenneth M Peters","doi":"10.1097/JU.0000000000004373","DOIUrl":"10.1097/JU.0000000000004373","url":null,"abstract":"<p><strong>Purpose: </strong>We assessed efficacy and safety of URO-902, an investigational gene therapy expressing the α subunit of the large-conductance Ca<sup>2+</sup>-activated K<sup>+</sup> channel, in a phase 2a placebo-controlled trial in women with overactive bladder (OAB).</p><p><strong>Materials and methods: </strong>Women, age 40 to 79 years, with OAB and urge urinary incontinence who were refractory to OAB medications were randomized to single-dose URO-902 24 and 48 mg or placebo administered by intradetrusor injection via cystoscopy under local anesthesia. Efficacy end points included change from baseline to week 12 in mean daily micturitions, urgency episodes, urge urinary incontinence episodes, and patient-reported outcomes. Safety assessments included adverse events and postvoid residual urine volume.</p><p><strong>Results: </strong>Of 80 patients randomized (URO-902 24 mg, n = 26; URO-902 48 mg, n = 27; placebo, n = 27), 74 received treatment, and 67 reached week 24. At week 12, URO-902 24 and 48 mg were associated with significant improvement vs placebo in daily micturitions (least-squares mean change from baseline, -2.3 and -2.4 vs -0.8, respectively; least-squares mean difference [95% CI], ‒1.5 [‒2.7 to ‒0.3] and ‒1.6 [‒2.8 to ‒0.4], nominal <i>P</i> = .017 and <i>P</i> = .009, respectively). URO-902 48 mg was associated with significant improvements vs placebo in urgency episodes (‒3.4 vs ‒1.1; ‒2.2 [‒4.0 to ‒0.4]; nominal <i>P</i> = .016) and percentage of Patient Global Impression of Change responders (58% vs 31%; nominal <i>P</i> = .026). Among patients receiving URO-902 24 mg, URO-902 48 mg, and placebo, 46%, 54%, and 54%, respectively, experienced ≥ 1 treatment-emergent adverse events, most commonly UTI (0%, 15%, 4%) and hematuria (6%, 8%, 8%).</p><p><strong>Conclusions: </strong>In this phase 2a trial, treatment with URO-902 was associated with improvements vs placebo in efficacy and patient-reported outcomes and was safe and well tolerated.</p>","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"417-427"},"PeriodicalIF":5.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial Comment. 编辑评论。
IF 5.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-04-01 Epub Date: 2024-12-23 DOI: 10.1097/JU.0000000000004379
Parth V Shah, Elizabeth L Koehne
{"title":"Editorial Comment.","authors":"Parth V Shah, Elizabeth L Koehne","doi":"10.1097/JU.0000000000004379","DOIUrl":"10.1097/JU.0000000000004379","url":null,"abstract":"","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"454"},"PeriodicalIF":5.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply by Authors.
IF 5.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-04-01 Epub Date: 2025-03-07 DOI: 10.1097/JU.0000000000004408
Gregory E Tasian, Jonathan D Harper, Hussein R Al-Khalidi, Hongqiu Yang, Naim M Maalouf, Michele Curatolo, H Henry Lai, Alana Desai, Jodi A Antonelli, Jing Huang, Justin B Ziemba, Hunter Wessells, Ziya Kirkali, Charles D Scales, Peter P Reese
{"title":"Reply by Authors.","authors":"Gregory E Tasian, Jonathan D Harper, Hussein R Al-Khalidi, Hongqiu Yang, Naim M Maalouf, Michele Curatolo, H Henry Lai, Alana Desai, Jodi A Antonelli, Jing Huang, Justin B Ziemba, Hunter Wessells, Ziya Kirkali, Charles D Scales, Peter P Reese","doi":"10.1097/JU.0000000000004408","DOIUrl":"https://doi.org/10.1097/JU.0000000000004408","url":null,"abstract":"","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":"213 4","pages":"483-484"},"PeriodicalIF":5.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-Term Urinary and Sexual Outcomes in Pediatric Genitourinary Rhabdomyosarcoma Survivors: A Qualitative Study. 儿童泌尿生殖系统横纹肌肉瘤幸存者的长期泌尿和性预后:一项定性研究。
IF 5.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-04-01 Epub Date: 2024-12-12 DOI: 10.1097/JU.0000000000004374
Rachel A Saunders, Andrea K Balthazar, Christopher D Jaeger, Monah Javidan-Nejad, Candace Y Chung, Judith A Vessey, Richard S Lee, Hsin-Hsiao Scott Wang

Purpose: Genitourinary rhabdomyosarcoma (GU-RMS) often requires multimodal therapy treatment including radiation, chemotherapy, and radical surgery for disease control. The long-term effects of the disease and associated treatments are unclear. We sought to investigate the long-term genitourinary quality of life for adult survivors of pediatric GU-RMS.

Materials and methods: In total, 14 participants (43% female, median age = 32.5 years [IQR = 23.25-39.25], range = 20-52 years, 2 bladder, 1 cervical, 5 paratesticular, 3 vaginal, 2 pelvic, and 1 prostate RMS) agreed to interview about impact of GU-RMS treatment during childhood on quality of life. A semistructured interview guide based on the long-term service and support quality-of-life model and grounded in known GU-RMS experiences was created. Two coders independently coded using thematic analysis methodology.

Results: Six themes emerged: (1) unknown fertility status; (2) lack of education; (3) relationships and difficult communication; (4) incontinence, clean intermittent catheterization, and a bag; (5) lifestyle and learned adaptation; and (6) threats to body image. Across these themes, participants reported insufficient knowledge regarding GU-RMS treatment and its impact on function. Participants were principally concerned with anatomical changes, fertility, pregnancy expectations, and survivorship challenges such as communication with romantic partners.

Conclusions: Survivors of GU-RMS have significant urinary and sexual function concerns that are important to address in long-term survivorship. Clinicians can potentially improve survivors' quality of life through open and honest age-appropriate education on expectations for treatment, fertility preservation options, and long-term effects of treatment.

目的:泌尿生殖系统横纹肌肉瘤(GU-RMS)通常需要放疗、化疗和根治性手术等多模式疗法来控制病情。该疾病及相关治疗的长期影响尚不明确。我们试图调查小儿GU-RMS成年幸存者的长期泌尿生殖系统生活质量:共有 14 名受试者(43% 为女性,中位年龄 = 32.5 岁 [IQR = 23.25 - 39.25],年龄范围 = 20 - 52 岁,2 名膀胱癌患者、1 名宫颈癌患者、5 名睾丸旁癌患者、3 名阴道癌患者、2 名盆腔癌患者、1 名前列腺 RMS 患者)同意就儿童期 GU-RMS 治疗对生活质量的影响进行访谈。根据长期服务和支持生活质量模型,并以已知的 GU-RMS 经验为基础,制定了一份半结构化访谈指南。两名编码员采用主题分析方法进行独立编码:出现了六个主题:(i) 生育状况不明,(ii) 缺乏教育,(iii) 人际关系和沟通困难,(iv) 大小便失禁、清洁间歇导尿和尿袋,(v) 生活方式和学习适应,以及 (vi) 身体形象受到威胁。在这些主题中,参与者表示对 GU-RMS 治疗及其对功能的影响缺乏足够的了解。参与者主要关注的是解剖学变化、生育能力、怀孕预期以及与恋爱伴侣沟通等幸存者面临的挑战:结论:GU-RMS 患者在泌尿和性功能方面有很大的问题,这些问题在长期存活过程中必须加以解决。临床医生可以通过开诚布公的、与年龄相适应的教育来提高幸存者的生活质量,教育内容包括对治疗的期望、保留生育能力的选择以及治疗的长期影响。
{"title":"Long-Term Urinary and Sexual Outcomes in Pediatric Genitourinary Rhabdomyosarcoma Survivors: A Qualitative Study.","authors":"Rachel A Saunders, Andrea K Balthazar, Christopher D Jaeger, Monah Javidan-Nejad, Candace Y Chung, Judith A Vessey, Richard S Lee, Hsin-Hsiao Scott Wang","doi":"10.1097/JU.0000000000004374","DOIUrl":"10.1097/JU.0000000000004374","url":null,"abstract":"<p><strong>Purpose: </strong>Genitourinary rhabdomyosarcoma (GU-RMS) often requires multimodal therapy treatment including radiation, chemotherapy, and radical surgery for disease control. The long-term effects of the disease and associated treatments are unclear. We sought to investigate the long-term genitourinary quality of life for adult survivors of pediatric GU-RMS.</p><p><strong>Materials and methods: </strong>In total, 14 participants (43% female, median age = 32.5 years [IQR = 23.25-39.25], range = 20-52 years, 2 bladder, 1 cervical, 5 paratesticular, 3 vaginal, 2 pelvic, and 1 prostate RMS) agreed to interview about impact of GU-RMS treatment during childhood on quality of life. A semistructured interview guide based on the long-term service and support quality-of-life model and grounded in known GU-RMS experiences was created. Two coders independently coded using thematic analysis methodology.</p><p><strong>Results: </strong>Six themes emerged: (1) unknown fertility status; (2) lack of education; (3) relationships and difficult communication; (4) incontinence, clean intermittent catheterization, and a bag; (5) lifestyle and learned adaptation; and (6) threats to body image. Across these themes, participants reported insufficient knowledge regarding GU-RMS treatment and its impact on function. Participants were principally concerned with anatomical changes, fertility, pregnancy expectations, and survivorship challenges such as communication with romantic partners.</p><p><strong>Conclusions: </strong>Survivors of GU-RMS have significant urinary and sexual function concerns that are important to address in long-term survivorship. Clinicians can potentially improve survivors' quality of life through open and honest age-appropriate education on expectations for treatment, fertility preservation options, and long-term effects of treatment.</p>","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"494-503"},"PeriodicalIF":5.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142818528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Tailored Electronic Survivorship Care Plan for Prostate Cancer Survivors: A Multicenter Randomized Controlled Trial. 为前列腺癌幸存者量身定制的电子生存护理计划:一项多中心随机对照试验。
IF 5.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-04-01 Epub Date: 2024-12-20 DOI: 10.1097/JU.0000000000004359
Jennifer M Jones, Andrew Matthew, Simon Tanguay, Celestia S Higano, Larry Goldenberg, Doris Howell, Manjula Maganti

Purpose: Although the provision of a survivorship care plan (SCP) has been recommended after prostate cancer (PCa) treatment, there have been no randomized controlled trials to examine their impact. The objective of this study was to evaluate the effect of a tailored PCa-SCP intervention provided to early-stage PCa survivors.

Materials and methods: A prospective, parallel 1:1 randomized controlled trial was conducted at 3 sites across Canada. Early-stage PCa survivors were randomized (n = 189; 64% response rate) to receive PCa-SCP intervention or usual care. Assessments were performed at baseline, 6 months, and 12 months. The primary outcome was change in patient activation (Patient Activation Measure-13); secondary outcomes included satisfaction with information, self-management support, prostate-specific quality of life, cancer worry, health care utilization, and health behaviors.

Results: For the primary patient activation analyses, no significant group-by-time differences were detected. There were significant between-group differences in (1) satisfaction with information from baseline to 6 months (mean [95% CI]: 7.13 [5.53-8.71]; effect size [ES], 0.34; P < .001) and baseline to 12 months (4.91 [3.06, 7.06]; ES, 0.19; P < .001); (2) social integration and support from baseline to 6 months (mean [95% CI]: 0.16 [0.06-0.26]; ES, 0.25; P = .002); and (3) skill and technique acquisition from baseline to 6 months (mean [95% CI]: 0.12 [-0.02 to 0.24]; ES, 0.33; P = .05). No other group-by-time differences were detected.

Conclusions: The PCa-SCP intervention did not have a significant effect on patient activation but did increase satisfaction with information and some aspects of self-management support. Although the benefits of the provision of an SCP alone remain unclear, the PCa-SCP intervention is likely a valuable tool that can be built upon as part of a comprehensive approach to enhance the quality of care for PCa survivors.

Trial registration: ClinicalTrials.gov Identifier: NCT03017456.

目的:尽管在前列腺癌(PCa)治疗后推荐提供生存护理计划(SCP),但没有随机对照试验来检验其影响。本研究的目的是评估为早期前列腺癌幸存者提供量身定制的PCa- scp干预的效果。材料和方法:在加拿大3个地点进行前瞻性、平行1:1随机对照试验。早期前列腺癌幸存者随机分组(n = 189;(有效率64%)接受PCa-SCP干预或常规护理。在基线、6个月和12个月时进行评估。主要结局是患者激活的改变(患者激活测量-13);次要结局包括信息满意度、自我管理支持、前列腺特异性生活质量、癌症担忧、医疗保健利用和健康行为。结果:对于初始患者激活分析,没有发现明显的组-时间差异。(1)从基线到6个月的信息满意度组间差异显著(平均[95% CI]: 7.13 [5.53-8.71];效应量[ES], 0.34;P < 0.001)和基线至12个月(4.91 [3.06,7.06],ES, 0.19, P < 0.001);(2)从基线到6个月的社会整合和支持(平均[95% CI]: 0.16 [0.06-0.26];ES 0.25;P = .002);(3)从基线到6个月的技能和技术获得(平均[95% CI]: 0.12[-0.02至0.24];ES 0.33;P = 0.05)。没有检测到其他按时间分组的差异。结论:PCa-SCP干预对患者激活没有显著影响,但确实增加了对信息和自我管理支持某些方面的满意度。虽然单独提供SCP的益处尚不清楚,但PCa-SCP干预可能是一种有价值的工具,可以作为提高PCa幸存者护理质量的综合方法的一部分。试验注册:clinicaltrials.gov标识符:NCT03017456。
{"title":"A Tailored Electronic Survivorship Care Plan for Prostate Cancer Survivors: A Multicenter Randomized Controlled Trial.","authors":"Jennifer M Jones, Andrew Matthew, Simon Tanguay, Celestia S Higano, Larry Goldenberg, Doris Howell, Manjula Maganti","doi":"10.1097/JU.0000000000004359","DOIUrl":"10.1097/JU.0000000000004359","url":null,"abstract":"<p><strong>Purpose: </strong>Although the provision of a survivorship care plan (SCP) has been recommended after prostate cancer (PCa) treatment, there have been no randomized controlled trials to examine their impact. The objective of this study was to evaluate the effect of a tailored PCa-SCP intervention provided to early-stage PCa survivors.</p><p><strong>Materials and methods: </strong>A prospective, parallel 1:1 randomized controlled trial was conducted at 3 sites across Canada. Early-stage PCa survivors were randomized (n = 189; 64% response rate) to receive PCa-SCP intervention or usual care. Assessments were performed at baseline, 6 months, and 12 months. The primary outcome was change in patient activation (Patient Activation Measure-13); secondary outcomes included satisfaction with information, self-management support, prostate-specific quality of life, cancer worry, health care utilization, and health behaviors.</p><p><strong>Results: </strong>For the primary patient activation analyses, no significant group-by-time differences were detected. There were significant between-group differences in (1) satisfaction with information from baseline to 6 months (mean [95% CI]: 7.13 [5.53-8.71]; effect size [ES], 0.34; <i>P</i> < .001) and baseline to 12 months (4.91 [3.06, 7.06]; ES, 0.19; <i>P</i> < .001); (2) social integration and support from baseline to 6 months (mean [95% CI]: 0.16 [0.06-0.26]; ES, 0.25; <i>P</i> = .002); and (3) skill and technique acquisition from baseline to 6 months (mean [95% CI]: 0.12 [-0.02 to 0.24]; ES, 0.33; <i>P</i> = .05). No other group-by-time differences were detected.</p><p><strong>Conclusions: </strong>The PCa-SCP intervention did not have a significant effect on patient activation but did increase satisfaction with information and some aspects of self-management support. Although the benefits of the provision of an SCP alone remain unclear, the PCa-SCP intervention is likely a valuable tool that can be built upon as part of a comprehensive approach to enhance the quality of care for PCa survivors.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT03017456.</p>","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"407-416"},"PeriodicalIF":5.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142869515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial Comment. 编辑评论。
IF 5.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-04-01 Epub Date: 2024-12-23 DOI: 10.1097/JU.0000000000004378
David-Dan Nguyen, Christopher J D Wallis
{"title":"Editorial Comment.","authors":"David-Dan Nguyen, Christopher J D Wallis","doi":"10.1097/JU.0000000000004378","DOIUrl":"10.1097/JU.0000000000004378","url":null,"abstract":"","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"415-416"},"PeriodicalIF":5.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial Comment. 编辑评论。
IF 5.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-04-01 Epub Date: 2025-01-07 DOI: 10.1097/JU.0000000000004402
Johar Raza
{"title":"Editorial Comment.","authors":"Johar Raza","doi":"10.1097/JU.0000000000004402","DOIUrl":"10.1097/JU.0000000000004402","url":null,"abstract":"","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"445"},"PeriodicalIF":5.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial Comment. 编辑评论。
IF 5.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-04-01 Epub Date: 2025-01-22 DOI: 10.1097/JU.0000000000004386
Mitchell G Goldenberg
{"title":"Editorial Comment.","authors":"Mitchell G Goldenberg","doi":"10.1097/JU.0000000000004386","DOIUrl":"10.1097/JU.0000000000004386","url":null,"abstract":"","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"510-511"},"PeriodicalIF":5.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial Comment. 编辑评论。
IF 5.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-04-01 Epub Date: 2024-12-20 DOI: 10.1097/JU.0000000000004382
Jason Y Lee
{"title":"Editorial Comment.","authors":"Jason Y Lee","doi":"10.1097/JU.0000000000004382","DOIUrl":"10.1097/JU.0000000000004382","url":null,"abstract":"","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"510"},"PeriodicalIF":5.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial Comment. 编辑评论。
IF 5.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-04-01 Epub Date: 2024-12-24 DOI: 10.1097/JU.0000000000004376
Luis H Braga, Melissa McGrath
{"title":"Editorial Comment.","authors":"Luis H Braga, Melissa McGrath","doi":"10.1097/JU.0000000000004376","DOIUrl":"10.1097/JU.0000000000004376","url":null,"abstract":"","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"492-493"},"PeriodicalIF":5.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Urology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1